Interferences by factor VIII and lupus anticoagulant in the modified one-stage assay for emicizumab

Haemophilia. 2023 Nov;29(6):1661-1664. doi: 10.1111/hae.14873. Epub 2023 Sep 25.

Authors

Capucine Habay¹, Claire Auditeau^{1

2}, Adeline Blandinières^{2

3}, Nûn K Bentounes¹, Cécile Lavenu-Bombled^{2

3}, Annie Harroche⁴, Cecile Bally⁴, Laurent Frenzel⁴, Delphine Borgel^{1

2}, Dominique Lasne^{1

2}

Affiliations

¹ Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France.
² Université Paris-Saclay, INSERM, Hémostase inflammation thrombose HITh U1176, Le Kremlin-Bicêtre, France.
³ Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁴ Centre de Traitement de l'Hémophilie, AP-HP, Hôpital Necker Enfants Malades, Paris, France.

PMID: 37751318
DOI: 10.1111/hae.14873

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / pharmacology
Antibodies, Bispecific* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Factor VIII / therapeutic use
Hemophilia A* / drug therapy
Hemostatics*
Humans
Lupus Coagulation Inhibitor

Substances

Factor VIII
emicizumab
Lupus Coagulation Inhibitor
Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Hemostatics